Comparison between Amster Labs IPO and Speciality Medicines IPO.
Amster Labs IPO is a SME Bookbuilding IPO proposed to list at NSE SME while Speciality Medicines IPO is a SME Bookbuilding proposed to list at BSE SME.
| Amster Labs IPO | Speciality Medicines IPO | |
|---|---|---|
| Logo |  |  |
| Issue Category | SME | SME |
| Issue Type | IPO | IPO |
| Process Type | Bookbuilding | Bookbuilding |
| Listing At | NSE SME | BSE SME |
| Lead Managers | Novus Capital Advisors Private Limited | Unistone Capital Pvt.Ltd. |
| Registrar | Skyline Financial Services Pvt.Ltd. | Skyline Financial Services Pvt.Ltd. |
| Market Maker | Aikyam Capital Private Limited | |
| DRHP | DRHP  | DRHP |
| RHP | RHP | RHP |
| Final Prospectus | Final Prospectus | Final Prospectus |
| Anchor Investor | ||
| IPO Allotment URL | IPO Allotment URL |
The total issue size of Amster Labs IPO is up to ₹0.00 Cr whereas the issue size of the Speciality Medicines IPO is up to ₹27.28 Cr. The final issue price of Amster Labs IPO is and of Speciality Medicines IPO is ₹124.00 per share.
| Amster Labs IPO | Speciality Medicines IPO | |
|---|---|---|
| Face Value | ₹10 per share | ₹10 per share |
| Issue Price (Lower) | ₹117.00 per share | |
| Issue Price (Upper) | ₹124.00 per share | |
| Issue Price (Final) | ₹124.00 per share | |
| Discount (Retail) | ||
| Discount (Employee) | ||
| Market Lot Size | 1000 shares | |
| Fresh Issue Size | 53,08,800 shares | 22,00,000 shares |
| Fresh Issue Size (Amount) | up to ₹0.00 Cr | up to ₹27.28 Cr |
| OFS Issue Size | 0 shares | 0 shares |
| OFS Issue Size (Amount) | up to ₹0.00 Cr | up to ₹0.00 Cr |
| Issue Size Total | 53,08,800 shares | 22,00,000 shares |
| Issue Size Total (Amount) | up to ₹0.00 Cr | up to ₹27.28 Cr |
Amster Labs IPO opens on , while Speciality Medicines IPO opens on Mar 20, 2026. The closing date of Amster Labs IPO and Speciality Medicines IPO is , and Mar 24, 2026, respectively.
| Amster Labs IPO | Speciality Medicines IPO | |
|---|---|---|
| Anchor Bid Date | ||
| Issue Open | Mar 20, 2026 | |
| Issue Close | Mar 24, 2026 | |
| Basis Of Allotment (Tentative) | Mar 25, 2026 | |
| Initiation of Refunds (Tentative) | Mar 27, 2026 | |
| Credit of Share (Tentative) | Mar 27, 2026 | |
| Listing date (Tentative) | Mar 30, 2026 | |
| Anchor Lockin End date 1 | ||
| Anchor Lockin End date 2 |
Amster Labs IPO P/E ratio is , as compared to Speciality Medicines IPO P/E ratio of 9.27.
| Amster Labs IPO | Speciality Medicines IPO | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financials | Company Financials (Restated)
| Company Financials (Restated Standalone)
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 72.79 | 59.28 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | 53.6 | 43.44 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| P/E Ratio | 9.27 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Market Cap | ₹108.94 Cr. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROE | 65.05 | 37.85 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROCE | 27.62 | 33.39 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt/Equity | 0.24 | 0.17 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EPS | ₹13.38 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RoNW | 28.30 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In the Amster Labs IPO Retail Individual Investors (RII) are offered while in Speciality Medicines IPO retail investors are offered . Qualified Institutional Buyers (QIB) are offered in Amster Labs IPO and 21,000 shares in Speciality Medicines IPO.
| Amster Labs IPO | Speciality Medicines IPO | |
|---|---|---|
| Anchor Investor Reservation | 0 shares | |
| Market Maker Reservation | 1,50,000 shares | |
| QIB | 21,000 shares | |
| NII | 10,89,000 shares | |
| RII | 10,90,000 shares | |
| Employee | 0 shares | |
| Others | ||
| Total | 22,00,000 shares |
Amster Labs IPO subscribed in total, whereas Speciality Medicines IPO subscribed 2.27x.
| Amster Labs IPO | Speciality Medicines IPO | |
|---|---|---|
| QIB (times) | 96.24x | |
| NII (times) | 1.88x | |
| Big NII (times) | 2.50x | |
| Small NII (times) | 0.64x | |
| RII (times) | 0.85x | |
| Employee (times) | ||
| Other (times) | ||
| Total (times) | 2.27x |
